Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Current Leases (2017 - 2023)

Historic Current Leases for Aclaris Therapeutics (ACRS) over the last 5 years, with Q4 2023 value amounting to $426000.0.

  • Aclaris Therapeutics' Current Leases fell 3771.93% to $426000.0 in Q4 2023 from the same period last year, while for Dec 2023 it was $426000.0, marking a year-over-year decrease of 3771.93%. This contributed to the annual value of $426000.0 for FY2023, which is 3771.93% down from last year.
  • As of Q4 2023, Aclaris Therapeutics' Current Leases stood at $426000.0, which was down 3771.93% from $310000.0 recorded in Q3 2023.
  • In the past 5 years, Aclaris Therapeutics' Current Leases registered a high of $766000.0 during Q3 2022, and its lowest value of $310000.0 during Q3 2023.
  • For the 3-year period, Aclaris Therapeutics' Current Leases averaged around $585125.0, with its median value being $643500.0 (2022).
  • Per our database at Business Quant, Aclaris Therapeutics' Current Leases tumbled by 129.87% in 2022 and then crashed by 5953.0% in 2023.
  • Aclaris Therapeutics' Current Leases (Quarter) stood at $693000.0 in 2021, then fell by 1.3% to $684000.0 in 2022, then crashed by 37.72% to $426000.0 in 2023.
  • Its Current Leases stands at $426000.0 for Q4 2023, versus $310000.0 for Q3 2023 and $458000.0 for Q2 2023.